No Data
No Data
Express News | NRx Pharmaceuticals Has Obtained Up To Approximately $16M In Convertible Debt Financing From An Institutional Investor To Support The 2024 New Drug Application Filing Its Two Lead Products, NRX-100 And NRX-101 And To Retire Existing Debt From...
Express News | NRX Pharmaceuticals - Intends to Use Net Proceeds From Financing to Support Nda Filing of NRX-100 and NRX-101
Express News | NRX Pharmaceuticals, Inc. (Nasdaq:Nrxp) Announces up to $16 Million Senior Secured Debt Financing From Anson Funds
HC Wainwright & Co. Maintains Buy on NRX Pharmaceuticals, Adjusts Price Target To $19 (1-10 Reverse Stock Split)
NRX Pharmaceuticals Analyst Ratings
Express News | NRX Pharmaceuticals Inc: Remains on Track to File Nda for NRX-100 in Q4 2024 With Anticipated Pdufa Date in Q2 2025
No Data